ArticleBMC neurology2026
Development and validation of programmed cell death related genes in intracranial aneurysms.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Intracranial aneurysm (IA) is a life-threatening condition. Programmed cell death (PCD) is central to aneurysm onset and progression. Nevertheless, a comprehensive analysis of the association between PCD and IA is lacking.We retrieved five IA-dataset including GSE13353, GSE15629, GSE26969, GSE54083, and GSE75436 from GEO database. After integrating these datasets, We calculated 9 cell death pattern scores via ssGSEA and identified ferroptosis and immunogenic cell death(ICD) as the higher relevance in the IA (AUC-ROC > 0.7).We relied on differential gene analysis and took intersections with ICD- and ferroptosis- genes, which was as the IA-PCD genes. Integrating Least absolute shrinkage and selection operator (LASSO) and support vector machine recursive feature elimination (SVM-RFE), identified two key genes, namely NLRP3 and HMOX1. In the dataset, the two genes were significantly overexpressed in patients with IA. Immune infiltration analysis showed that NLRP3 and HMOX1 could influence the extent of immune cell infiltration.For further validation, we found that the expression levels of NLRP3 and HMOX1 in the serum of IA patients were significantly higher than those in the normal group though Elisa, consistenting with the bioinformatics result. In conclusion, NLRP3 and HMOX1 are associated with IA. These findings provide a basis for further exploring potential molecular driving mechanisms and screening suitable biomarkers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.